Biocon’s wholly owned subsidiary - Biocon Research (BRL), has entered into an agreement with GE Equity International Mauritius, a subsidiary of GE Capital Corporation (GE Capital), to purchase the latter’s investment in Biocon’s research services subsidiary, Syngene International for an agreed consideration of Rs 215.38 crore. GE Capital had a 7.69% stake in Syngene.
Syngene offers integrated drug discovery and development services with capabilities in medicinal chemistry, biology, in vivo pharmacology and toxicology.
Biocon is India’s largest and Asia's leading biotechnology company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation-driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.
